DK1633733T3 - Cannabinoidderivater, fremstillingsmåder og anvendelse deraf - Google Patents
Cannabinoidderivater, fremstillingsmåder og anvendelse derafInfo
- Publication number
- DK1633733T3 DK1633733T3 DK04752828.6T DK04752828T DK1633733T3 DK 1633733 T3 DK1633733 T3 DK 1633733T3 DK 04752828 T DK04752828 T DK 04752828T DK 1633733 T3 DK1633733 T3 DK 1633733T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- methods
- cannabinoid derivatives
- tetrahydrocannabinol
- delta
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 2
- 239000003557 cannabinoid Substances 0.000 title abstract 2
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 abstract 4
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 abstract 4
- 102000008906 Cannabinoid receptor type 2 Human genes 0.000 abstract 4
- 108050000860 Cannabinoid receptor type 2 Proteins 0.000 abstract 4
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 abstract 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical class C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 abstract 1
- 229960004242 dronabinol Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47231603P | 2003-05-20 | 2003-05-20 | |
| PCT/US2004/015885 WO2004113320A1 (en) | 2003-05-20 | 2004-05-20 | Cannabinoid derivatives, methods of making, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1633733T3 true DK1633733T3 (da) | 2011-05-16 |
Family
ID=33539041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04752828.6T DK1633733T3 (da) | 2003-05-20 | 2004-05-20 | Cannabinoidderivater, fremstillingsmåder og anvendelse deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7169942B2 (enExample) |
| EP (1) | EP1633733B1 (enExample) |
| JP (1) | JP2007501279A (enExample) |
| CN (1) | CN1809552A (enExample) |
| AT (1) | ATE496901T1 (enExample) |
| AU (1) | AU2004249669B2 (enExample) |
| CA (1) | CA2526103A1 (enExample) |
| DE (1) | DE602004031221D1 (enExample) |
| DK (1) | DK1633733T3 (enExample) |
| WO (1) | WO2004113320A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005093052A1 (en) * | 2004-03-26 | 2005-10-06 | Fuji Photo Film Co., Ltd. | Method for selectively separating and purifying rna and method for separating and purifying nucleic acid |
| USRE46558E1 (en) | 2005-04-28 | 2017-09-26 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| AU2006297300B2 (en) * | 2005-09-29 | 2012-05-10 | Albany Molecular Research, Inc. | Process for production of delta-9-tetrahydrocannabinol |
| DE102005062098A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Oxaphenanthren-Derivate |
| JP2009528381A (ja) * | 2006-02-28 | 2009-08-06 | パロマ ファーマシューティカルズ，インク． | 細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法 |
| WO2008109027A2 (en) | 2007-03-02 | 2008-09-12 | University Of Tennessee Research Foundation, The | Tri-aryl/heteroaroaromatic cannabinoids and use thereof |
| AU2009228303B2 (en) * | 2008-03-25 | 2015-08-13 | Paloma Pharmaceuticals, Inc. | Methods of treating fibrotic disorders |
| US8022078B2 (en) | 2008-05-19 | 2011-09-20 | University Of Tennessee Research Foundation | Pyrimidine classical cannabinoid compounds and related methods of use |
| CA2724697A1 (en) * | 2008-05-19 | 2009-11-26 | University Of Tennessee Research Foundation, The | Pyridine classical cannabinoid compounds and related methods of use |
| US8389534B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US8476439B2 (en) | 2008-05-19 | 2013-07-02 | The University Of Tennessee Research Foundation | Pyridine classical cannabinoid compounds and related methods of use |
| CA2724737A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US8349876B2 (en) * | 2008-05-19 | 2013-01-08 | The University Of Tennesee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| US8158654B2 (en) | 2008-05-19 | 2012-04-17 | The University Of Tennessee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| EP2309858A4 (en) | 2008-07-31 | 2011-09-14 | Dekel Pharmaceuticals Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| WO2012112791A1 (en) | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| CN103110582A (zh) * | 2013-03-04 | 2013-05-22 | 上海医药工业研究院 | 大麻酚类化合物微乳剂及其制备方法 |
| CA2952934A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
| US20170008869A1 (en) * | 2015-07-10 | 2017-01-12 | Noramco, Inc. | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol |
| IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Formulations of dilutable cannabinoids and processes for their preparation |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| US20180169061A1 (en) * | 2016-12-15 | 2018-06-21 | Ascent Pharmaceuticals, Inc. | Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations |
| EP3672587A4 (en) | 2017-08-27 | 2021-05-19 | Rhodes Technologies | PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| KR102880573B1 (ko) * | 2018-08-20 | 2025-11-04 | 베서, 파마 엘엘씨 | 칸나비노이드의 생성 공정 |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| CN110269839A (zh) * | 2019-06-15 | 2019-09-24 | 云南飞久逍科技有限公司 | 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用 |
| CN114727960A (zh) * | 2019-10-03 | 2022-07-08 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 数个脂质体大麻素及其用途 |
| EP4054335A4 (en) | 2019-11-08 | 2023-09-27 | Vella Bioscience, Inc. | Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941782A (en) | 1972-04-27 | 1976-03-02 | Sharps Associates | Heterocyclic esters of benzopyrans |
| US3915996A (en) * | 1972-10-16 | 1975-10-28 | Abbott Lab | Process for making benzopyrans |
| US3901926A (en) | 1973-04-02 | 1975-08-26 | Abbott Lab | Alkylphenyl benzopyrans |
| DE4100441A1 (de) * | 1991-01-09 | 1992-07-16 | Mack Chem Pharm | Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| CA2278307A1 (en) | 1997-01-21 | 1998-07-23 | Siegfried Benjamin Christensen Iv | Novel cannabinoid receptor modulators |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| DE19706903A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
| EP0979228A4 (en) | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| US5939429A (en) | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
| ATE247097T1 (de) * | 1998-05-04 | 2003-08-15 | Univ Connecticut | Analgetische und immunomodulierende cannabinoiden |
| US6563009B1 (en) | 1999-07-12 | 2003-05-13 | Virginia Commonwealth University | Vasodilator cannabinoid analogs |
| FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| IL132661A (en) | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| EP1299374B1 (en) * | 2000-06-22 | 2006-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| CA2466440A1 (en) | 2001-11-14 | 2003-05-22 | Schering Corporation | Cannabinoid receptor ligands |
| AU2003243637A1 (en) | 2002-06-19 | 2004-01-06 | Schering Corporation | Cannabinoid receptor agonists |
| JP2006506366A (ja) | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
-
2004
- 2004-05-20 EP EP04752828A patent/EP1633733B1/en not_active Expired - Lifetime
- 2004-05-20 AT AT04752828T patent/ATE496901T1/de not_active IP Right Cessation
- 2004-05-20 CA CA002526103A patent/CA2526103A1/en not_active Abandoned
- 2004-05-20 AU AU2004249669A patent/AU2004249669B2/en not_active Ceased
- 2004-05-20 JP JP2006533257A patent/JP2007501279A/ja active Pending
- 2004-05-20 DK DK04752828.6T patent/DK1633733T3/da active
- 2004-05-20 WO PCT/US2004/015885 patent/WO2004113320A1/en not_active Ceased
- 2004-05-20 US US10/850,588 patent/US7169942B2/en not_active Expired - Fee Related
- 2004-05-20 CN CNA2004800174008A patent/CN1809552A/zh active Pending
- 2004-05-20 DE DE602004031221T patent/DE602004031221D1/de not_active Expired - Lifetime
-
2007
- 2007-01-26 US US11/698,665 patent/US20070167514A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004031221D1 (de) | 2011-03-10 |
| US20040242593A1 (en) | 2004-12-02 |
| EP1633733A1 (en) | 2006-03-15 |
| AU2004249669A1 (en) | 2004-12-29 |
| EP1633733B1 (en) | 2011-01-26 |
| AU2004249669B2 (en) | 2008-05-22 |
| CA2526103A1 (en) | 2004-12-29 |
| US20070167514A1 (en) | 2007-07-19 |
| EP1633733A4 (en) | 2007-02-28 |
| US7169942B2 (en) | 2007-01-30 |
| WO2004113320A1 (en) | 2004-12-29 |
| CN1809552A (zh) | 2006-07-26 |
| ATE496901T1 (de) | 2011-02-15 |
| JP2007501279A (ja) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1633733T3 (da) | Cannabinoidderivater, fremstillingsmåder og anvendelse deraf | |
| BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
| NO20010446L (no) | Substituert anilidforbindelser og metoder | |
| DE69422191D1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
| CR6478A (es) | Moduladores del receptor glucocorticoide | |
| NO983431D0 (no) | Anti-kl°emidler | |
| UY25794A1 (es) | Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a | |
| ME01291A (me) | Derivati prikolinamida kao inhibitori kinaze | |
| ECSP034656A (es) | Derivados benzimidazol y piridilimidazol como ligandos para gabaa | |
| DK1199069T3 (da) | Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed | |
| ATE322258T1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
| NO20011440L (no) | mGluR5-antagonister for behandling av smerte og angst | |
| EE200100243A (et) | 5HT1 retseptori agonistid ja metoklopramiid migreeni raviks | |
| CY1110443T1 (el) | Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων | |
| DE69626705D1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
| BR0311436A (pt) | Derivados de 1-(aminoalquil)-3-sulfoni-lindol e -indazol como ligandos da 5-hidroxitriptamina-6 | |
| ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
| PT1267869E (pt) | Antogonistas de receptor de glutamato metabotropico para o tratamento de tolerancia e de dependencia | |
| EP1305023A4 (en) | USE OF ADENOSINE A1 RECEPTOR SELECTIVE ALLOSTERIC AGONISTS, ANTAGONISTS AND AMPLIFIERS TO MANIPULATE ANGIOGENESIS | |
| TR199700956T1 (xx) | Indazolkarboksamidler. | |
| DE60314896D1 (de) | 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert | |
| BR0307903A (pt) | derivados de arilsulfona | |
| AU5614198A (en) | Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors | |
| DE60236848D1 (de) | 8-ä4-Ä3-(5-FLUORO-1H-INDOL-3-YL)PROPYLÜ -1-PIPERAZINYLü -2-METHYL-2H-1, 4-BENZOXAZIN-3(4H)-ON METHANESULFONAT MIT HOHER AFFINITÄT FÜR DEN DOPAMIN D2 REZEPTOR UND DEN SEROTONIN REUPTAKE SITE |